|
Dr. Chu is Professor of Medicine and Pharmacology at the Yale University School of Medicine. He received his M.D. degree from Brown University where he also completed his residency training in internal medicine. At the National Cancer Institute, his fellowship training was in medical oncology, where he became a Senior Clinical Investigator before coming to Yale in 1996. He is currently the Co-Director of the Developmental Therapeutics Program at the Yale Cancer Center. Dr. Chu is well known for his investigations concerning resistance to fluoropyrimidines and in the understanding of the regulation of expression of thymidylate synthase. This work is of significant importance to ADVENTRX because of its lead cancer compound CoFactor, which is used with fluoropyrimidines to target TS inhibition. | 